---
title: "SIAS urges shareholders to await IFA opinion on Singapore Paincare offer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/243192539.md"
description: "The Securities Investors Association (Singapore) (SIAS) advises minority shareholders of Singapore Paincare Holdings to wait for the independent financial adviser (IFA) report before selling shares. This follows a privatisation offer of $0.16 per share from Advance Bridge Healthcare Pte. Ltd. SIAS warns that selling before the IFA's advice may result in lower gains, especially if the offer price is revised upward. The offer is slightly below the company's audited net asset value of $0.166 per share as of June 30, 2024, and requires shareholder approval for delisting."
datetime: "2025-06-05T02:31:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/243192539.md)
  - [en](https://longbridge.com/en/news/243192539.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/243192539.md)
generator: "portal-rs"
---

# SIAS urges shareholders to await IFA opinion on Singapore Paincare offer

**Shareholders may gain less if they sell before the IFA’s advice.**

The Securities Investors Association (Singapore) (SIAS) advises minority shareholders of Singapore Paincare Holdings not to sell their shares yet and wait until the independent financial adviser (IFA) has issued its report.

On 28 May, Singapore Paincare Holdings received a privatisation offer of $0.16 per share from Advance Bridge Healthcare Pte. Ltd. via a scheme of arrangement.

SIAS said it issued the notice because some shareholders had previously sold shares before the IFA's opinion, seeking slight gain.

However, SIAS noted that if shares are sold in the open market, shareholders who sold will not have recourse if there is a subsequent upward revision in the offer price.

The offer price is at a slight discount to the company’s audited net asset value (NAV) per share of $0.166 as of 30 June 2024, whilst the unaudited NAV as of 31 December 2024 stands at $0.163 per share.

The delisting is subject to the approval of over 50% of shareholders by headcount and 75% in share value at the scheme meeting. The IFA also needs to conclude whether the offer is both fair and reasonable.

### Related Stocks

- [FRQ.SG](https://longbridge.com/en/quote/FRQ.SG.md)

## Related News & Research

- [Singapore Paincare says no change in creditors’ voluntary winding-up of 51%-owned DLS unit](https://longbridge.com/en/news/294043651.md)
- [Singapore Paincare appoints UOB Kay Hian as continuing sponsor, replacing Novus](https://longbridge.com/en/news/294044658.md)
- [Analyst Raises Price Target to C$4.25 and Reiterates Buy Rating on Omai Gold Project’s Enhanced 18-Year Production Profile](https://longbridge.com/en/news/296636529.md)
- [Oil set for second weekly rise as unsettled US-Iran war crimps supply](https://longbridge.com/en/news/296555193.md)
- [Southern Copper (NYSE:SCCO) Shares Up 8.3%  - Still a Buy?](https://longbridge.com/en/news/296638179.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**